Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

real-time data

- PMLiVE

Vertex and Genomics expand collaboration to accelerate precision medicines

The partners have been working together since 2018 to develop treatments for serious diseases

- PMLiVE

Camurus shares positive late-stage results for investigational acromegaly treatment

The rare disease has an estimated prevalence of approximately 60 cases per million

- PMLiVE

AI tool better predicts progress of Alzheimer’s versus current clinical tests

The most common form of dementia accounts for up to 80% of all cases

- PMLiVE

Pfizer to advance once-daily formulation of oral GLP-1 receptor agonist danuglipron

The drugmaker said last year that it would be dropping its twice-daily formulation of the candidate

- PMLiVE

Lexeo’s gene therapy candidate shows promise in Friedreich’s ataxia cardiomyopathy

The neurodegenerative movement disorder affects approximately one in every 40,000 people

- PMLiVE

ICR study reveals Lynparza could treat more advanced prostate cancer patients

Up to 30% of men living with the advanced disease have tumours that contain defects in repairing DNA

- PMLiVE

Researchers identify free light chain targets to help treat rare form of amyloidosis

AL amyloidosis is currently the most common and severe form of the condition

Doctor speaking to patient and clinical setting in Cuttsy+Cuttsy branded shapes

Compliance — a driving force for influencing public perceptions of the pharma industry?

How does compliance play into public perceptions of pharma and why is it important for improving public opinion?

Cuttsy + Cuttsy

- PMLiVE

Roche’s subcutaneous Ocrevus granted MHRA approval to treat relapsing and primary MS

The NHS said it expects stock of the ten-minute injection to be available in the coming weeks

- PMLiVE

Novo Nordisk’s Ozempic associated with cognitive benefits in diabetes patients

Researchers from the University of Oxford analysed records from more than 100 million patients in the US

- PMLiVE

Immutep’s LAG-3 immunotherapy candidate shows promise in head and neck cancer

Approximately 600,000 new cases of head and neck squamous cell carcinoma are diagnosed globally every year

- PMLiVE

Phesi publishes new analysis revealing top five most studied diseases globally

The analysis also showed that 32% of phase 2 trials were terminated in the first half of 2024

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links